NCT03026062 2025-09-19
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
14 trialsNCT03085225 2025-09-04
TRAMUNE
Institut Bergonié
Phase 1 Completed
NCT03518606 2025-01-15
MOVIE
UNICANCER
Phase 1/2 Completed
NCT02953457 2024-11-19
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
Phase 2 Completed
NCT04504669 2024-11-05
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT03830866 2024-07-26
CALLA
AstraZeneca
Phase 3 Completed
NCT03452332 2023-09-13
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02963831 2022-12-22
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT01975831 2022-10-12
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02431559 2022-10-10
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02764333 2021-11-30
TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02811497 2021-04-01
METADUR
University Health Network, Toronto
Phase 2 Completed
NCT02725489 2021-01-27
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
Mary Crowley Medical Research Center
Phase 2 Completed
NCT03430518 2020-08-05
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed